10,060 results match your criteria Dermatomyositis


Clinical features of thirty-two patients with anti-melanoma differentiation-associated gene 5 antibodies.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Rheumatology and Immunology of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Objectives: To investigate the clinical characteristics of patients positive for anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, and to analyse the potential pathogenesis of anti-MDA5 antibodies.

Methods: The clinical manifestations, serological tests, imaging features, treatments, and prognoses of 32 anti-MDA5 antibody-positive patients diagnosed in the Rheumatology and Immunology Department of the Second Affiliated Hospital of Chongqing Medical University from September 2015 to August 2018 were analysed.

Results: Of the 32 anti-MDA5 antibody-positive patients, eleven patients were clinically diagnosed with interstitial pneumonia with autoimmune features (IPAF), ten patients were diagnosed with clinically amyopathic dermatomyositis (CADM), six patients were diagnosed with dermatomyositis (DM) and five patients were diagnosed with anti-synthetase syndrome (ASS). Read More

View Article

Download full-text PDF

Source
February 2019

Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome.

J Immunol Res 2019 14;2019:9141420. Epub 2019 Jan 14.

INSERM U976, Laboratory of Oncodermatology, Immunology, and Cutaneous Stem Cells, Hôpital Saint-Louis, Paris, France.

Dermatomyositis pathophysiology is complex. In recent years, medical research has identified molecules associated with disease activity. Besides providing insights into the driving mechanisms of dermatomyositis, these findings could provide potential biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/9141420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350546PMC
January 2019

Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture.

Respirol Case Rep 2019 Apr 4;7(3):e00403. Epub 2019 Feb 4.

Department of Respiratory Medicine Kyorin University School of Medicine Tokyo Japan.

A 58-year-old man presented with a two-month history of facial erythema and dry cough. Physical examination revealed typical cutaneous manifestations of dermatomyositis (DM), including heliotrope rash and shawl sign. A chest X-ray revealed a 4-cm mass in the right middle lung. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcr2.403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360367PMC

Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance.

Eur J Med Res 2019 Feb 14;24(1):12. Epub 2019 Feb 14.

Department of Immunology, No. 983 of the Chinese People's Liberation Army Joint Support Force, No. 60 of Huangwei Street, Hebei District, Tianjin, 300142, China.

Objective: This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.

Methods: Serum MCP-1 and TGF-β1 levels in PM/DM patients complicated with ILD, patients with pulmonary infections and normal controls (n = 30, each) were detected using enzyme-linked immunosorbent assay (ELISA), and the correlation between PM/DM complicated with ILD and serum MCP-1 and TGF-β1 levels was analyzed.

Results: Serum MCP-1 and TGF-β1 levels were both higher in PM/DM patients complicated with ILD compared with patients with pulmonary infections and normal controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40001-019-0368-7DOI Listing
February 2019

Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter's syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus.

J Dtsch Dermatol Ges 2019 Feb;17(2):167-181

Department of Rheumatology and clinical Immunology, Freiburg University Medical Center, Medical Faculty, Albert Ludwigs University, Freiburg, Germany.

Syndromes associated with concurrent skin and joint inflammation frequently pose a therapeutic challenge for both dermatologists and rheumatologists. In part 1 of this review, we discussed psoriatic arthritis as well as the autoinflammatory disorders SAPHO syndrome, Still's disease and Behçet's disease. Part 2 will address rheumatoid arthritis, reactive arthritis, Reiter's syndrome and Lyme borreliosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13761DOI Listing
February 2019

Hautentzündungen mit Arthritis, Synovitis und Enthesitis. Teil 2: Rheumatoide Arthritis, reaktive Arthritis, Morbus Reiter, Lyme-Borreliose, Dermatomyositis und Lupus erythematodes.

J Dtsch Dermatol Ges 2019 Feb;17(2):167-182

Klinik für Rheumatologie und klinische Immunologie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13761_gDOI Listing
February 2019

Dermatomyositis Associated with Sarcoidosis: Two Cases.

Eur J Case Rep Intern Med 2017 27;4(1):000500. Epub 2017 Jan 27.

Department of Rheumatology and Physical Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Dermatomyositis (DM) and sarcoidosis are two idiopathic systemic disorders. Reports of patients with both conditions are extremely rare. Here we describe two patients who presented with DM and DM-associated antibodies, and later developed biopsy-proven sarcoidosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2016_000500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346918PMC
January 2017

EBV-Associated Non-keratinizing Nasopharyngeal Carcinoma with Prominent Spindled Cell and Whorling Patterns: A Previously Unreported Histological Variant in a Patient Presenting with Dermatomyositis.

Head Neck Pathol 2019 Feb 13. Epub 2019 Feb 13.

Department of Pathology, National University Health System, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore.

A case of non-keratinizing, EBV-positive (chromogenic EBER-in situ hybridization), carcinoma with a hitherto undescribed nodular whorling architecture is presented. The patient is a 55 year old male with 2 months history of dermatomyositis who was diagnosed with T1N0M0 non-keratinizing nasopharyngeal carcinoma. The patient received radiotherapy with complete response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12105-019-01019-zDOI Listing
February 2019

Paraneoplastic dermatomyositis presenting with interesting cutaneous findings.

Cutis 2019 Jan;103(1):E17-E19

Keck School of Medicine of the University of Southern California, Los Angeles, USA.

View Article

Download full-text PDF

Source
January 2019

Breast Cancer with Paraneoplastic Syndrome in a 72 Year Old Male Patient.

Mymensingh Med J 2019 Jan;28(1):254-258

Dr Sabrina Yesmin, Associate Professor and Head, Department of Medicine, Dr Sirajul Islam Medical College Hospital, Dhaka, Bangladesh; E-mail:

Breast cancer in male is rare which accounts about 1% of all malignant breast neoplasm cases. Since paraneoplastic syndrome is unusual with male breast cancer, very few reported cases are found. A72- year-old gentleman presented with proximal myopathy in all four limbs was referred to Dr. Read More

View Article

Download full-text PDF

Source
January 2019

Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis.

Dermatol Ther 2019 Feb 12:e12859. Epub 2019 Feb 12.

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12859DOI Listing
February 2019

Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.

Clin Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.

In the past decade, lung ultrasound (LUS) B-lines and serum Krebs von den Lungen-6 (KL-6) antigen have been recognized as biomarkers of the connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Robust data have demonstrated that B-lines total numbers and KL-6 levels are correlated with high-resolution computed tomography findings, pulmonary function test, and some clinical parameters in CTD-ILDs. However, limited data are available regarding the use of these two biomarkers to follow CTD-ILDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04462-zDOI Listing
February 2019
1 Read

Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients.

JAAD Case Rep 2019 Feb 30;5(2):191-194. Epub 2019 Jan 30.

Department of Dermatology, Tulane University, New Orleans, Louisiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.11.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357541PMC
February 2019
1 Read

Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases.

Front Immunol 2019 25;10:46. Epub 2019 Jan 25.

Division of Infection and Immunity, Institute of Immunity and Transplantation, University College London, London, United Kingdom.

Regulatory T cells (Tregs) are believed to be dysfunctional in autoimmunity. Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) result from a loss of normal immune regulation in specific tissues such as joints or muscle and skin, respectively. Here, we discuss recent findings in regard to Treg biology in oligo-/polyarticular JIA and JDM, as well as what we can learn about Treg-related disease mechanism, treatment and biomarkers in JIA/JDM from studies of other diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355674PMC
January 2019
1 Read

Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Clin Rheumatol 2019 Feb 9. Epub 2019 Feb 9.

Department of Medicine, Nanchang University, Nanchang, 330006, Jiangxi Province, China.

Objective: We aimed to investigate the clinical value of checking serum chitinase-3-like-1 protein (YKL-40) levels in anti-MDA5 antibody-positive dermatomyositis (anti-MDA5DM) patients.

Methods: One hundred and five consecutive anti-MDA5DM patients and 44 healthy controls were enrolled in this study. Baseline and follow-up serum YKL-40 were detected by ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04457-wDOI Listing
February 2019
1 Read

Clinical Factors Associated with Cutaneous Histopathologic Findings in Dermatomyositis.

J Cutan Pathol 2019 Feb 9. Epub 2019 Feb 9.

Department of Dermatology, Stanford University School of Medicine, Stanford, CA.

Background: Common histopathologic findings in cutaneous dermatomyositis include vacuolar interface with dyskeratosis, mucin, and perivascular inflammation. Data examining the relationships between these and other histologic abnormalities, or their dependence on biopsy site, and medications is limited.

Methods: Using 228 dermatomyositis skin biopsies and statistical analyses including Chi-squared analyses, calculations of relative risk, and adjusted GEE regressions we investigated relationships between 14 histopathologic findings and the impact of clinical factors on these findings. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cup.13442
Publisher Site
http://dx.doi.org/10.1111/cup.13442DOI Listing
February 2019
5 Reads

Cutaneous paraneoplastic syndromes.

Semin Diagn Pathol 2019 Jan 31. Epub 2019 Jan 31.

PRW Laboratories, Charlottesville, VA, United State.

A variety of cutaneous abnormalities can be seen in patients with malignant diseases, some of which are infectious, with others representing direct involvement of the skin by the underlying disorder. Yet another group of lesions can be regarded as associated markers of the malignant process, and, as such, are termed "paraneoplastic." This review considers the latter collection of conditions, grouping them by the generic type of malignancy that is usually linked to the paraneoplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2019.01.001DOI Listing
January 2019
1 Read

Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.

Respir Med Case Rep 2019 14;26:193-196. Epub 2019 Jan 14.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan.

A 47-year-old man was referred to our hospital with a 1-month history of fever and dyspnea after inhalation of insecticide in a confined space. We diagnosed rapidly progressive interstitial pneumonia. High-dose methylprednisolone, tacrolimus, and intermittent infusion of cyclophosphamide were administered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350262PMC
January 2019
1 Read

Elevated plasma D-dimer levels in dermatomyositis patients with cutaneous manifestations.

Sci Rep 2019 Feb 5;9(1):1410. Epub 2019 Feb 5.

Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.

To explore the influence of dermatomyositis (DM)-specific cutaneous manifestations (scm) on systemic coagulation and fibrinolysis, we retrospectively studied plasma D-dimer levels with/without venous thromboembolism (VTE), malignancy, infection or other connective tissue diseases (CTDs) and scm. One hundred fifty patients with DM were retrospectively investigated using medical records regarding scm, VTE, malignancy, infection, other CTDs, laboratory data and systemic corticosteroid therapy. All DM patients were categorized as follows: group 1, without scm, VTE, infection, malignancy or other accompanying CTDs; group 2, with scm only; and group 3, with VTE, infection, malignancy and other accompanying CTDs but without scm. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-38108-y
Publisher Site
http://dx.doi.org/10.1038/s41598-018-38108-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363793PMC
February 2019
3 Reads

Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India.

J Clin Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

Objectives: Idiopathic inflammatory myositis (IIM) commonly affects women in the childbearing age group. Both disease activity and immunosuppressants used may have adverse effects on fertility and outcomes of pregnancy. We explored these outcomes in a retrospective cohort of women with IIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000996DOI Listing
February 2019
3 Reads

Giant thoracic calcinosis: a dermatomyositis manifestation.

Rheumatology (Oxford) 2019 Jan 30. Epub 2019 Jan 30.

Unit of Autoimmune Disease, San Cecilio University Hospital, Granada, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez013DOI Listing
January 2019
3 Reads

Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Brain 2019 Feb 1. Epub 2019 Feb 1.

Sorbonne Université, INSERM UMRS_974, Center of Research in Myology, AP-HP, Department of Internal Medicine and Clinical Immunology, DHU I2B, Pitié-Salpêtrière Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz006DOI Listing
February 2019
1 Read

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Brain 2019 Feb 1. Epub 2019 Feb 1.

Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz005DOI Listing
February 2019
1 Read

Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice.

J Neuromuscul Dis 2019 ;6(1):99-107

Department of Internal Medicine and Clinical Immunology, National Reference Center of Neuromuscular disorders, Pitié-Salpêtrière University Hospital, Sorbonne Université, Paris, France.

Background: Manual muscle testing has been widely used for the evaluation of muscle strength in myositis, yet less attention has been devoted to the evaluation of muscle function and endurance.

Objective: Our objective was therefore to compare the responsiveness to change of muscle strength, endurance and functional testing following induction therapy for severe myositis flare (requiring high-dose corticosteroids and combined immunotherapy) in patients with a diagnosis of dermatomyositis, immune-mediated necrotizing myopathy, or overlap myositis.

Methods: Muscle status was assessed at baseline and after mean 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JND-180358DOI Listing
January 2019
2 Reads

The Association of Short-term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis.

Arthritis Care Res (Hoboken) 2019 Feb 4. Epub 2019 Feb 4.

University of California, San Francisco.

Objective: Ultraviolet radiation (UVR) is considered to be an important environmental factor in the clinical course of children with JDM. We aimed to evaluate the association between UVR and severe disease outcomes in JDM.

Methods: This is a cross-sectional study of JDM subjects enrolled in the U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23840DOI Listing
February 2019
1 Read

Strategy for Suspected Myositis.

Joint Bone Spine 2019 Jan 31. Epub 2019 Jan 31.

Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France; Centre de Référence des Maladies Autoimmunes Rares de l'Est & Sud Ouest, 33000 Bordeaux, France; Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, 67081 Strasbourg, France.

Skeletal muscle inflammation is the feature shared by all forms of myositis. However, the muscle damage ranges in severity from asymptomatic to responsible for severe weakness. In addition, myositis usually occurs as a systemic disease that affects multiple organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2019.01.013DOI Listing
January 2019
1 Read

Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology.

Indian J Pathol Microbiol 2019 Jan-Mar;62(1):61-66

Department of Neurology, Institute of Neurological Sciences, Care Hospital, Hyderabad, Telangana, India.

Background: Juvenile idiopathic inflammatory myopathies (JIIM) are rare and heterogeneous. Subtype identification is important for treatment.

Materials And Methods: Patients below 18 years diagnosed as idiopathic inflammatory myopathy (IIM) according to the Bohan and Peter criteria between January 2010 and May 2015 were evaluated with muscle biopsy in the four domains: muscle fiber, inflammation, connective tissue, and vascular, with basic panel of histochemical stains as per recommendations of the European Neuromuscular center (ENMC) workshop 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_387_17DOI Listing
February 2019
1 Read

Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review.

J Cosmet Dermatol 2019 Jan 29. Epub 2019 Jan 29.

The Dermatology, Wuhan University Zhongnan Hospital, Wuhan, Hubei, China.

Introduction: The incidence rate of psoriasis vulgaris (PSV) coexisting with Juvenile dermatomyositis (JDM) is low. Through our thorough literature search, we found that PSV arising on JDM with superficial fungal infection of facial skin is rarely reported. So, we hereby, report a case of combination of the above three diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.12869DOI Listing
January 2019
2 Reads

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.

Prostate Cancer Prostatic Dis 2019 Jan 28. Epub 2019 Jan 28.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

Background: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.

Methods: We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox proportional hazards models with 1:1 propensity score-matched analysis were used to investigate the association between ADT use and the risk of autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0130-9
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0130-9DOI Listing
January 2019
5 Reads

[A Case of Cecal Cancer Associated with Dermatomyositis].

Gan To Kagaku Ryoho 2018 Dec;45(13):2196-2198

Dept. of Surgery, Kindai University Faculty of Medicine.

We report a relatively rare case of cecal cancer with dermatomyositis. An 81-year-old man was diagnosed with dermatomyositis associated with the symptoms of eruption, limb muscle weakness, and difficulty swallowing. Colonoscopy revealed a type 2 tumor in the cecum. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

A case of dermatomyositis with the anti-signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy.

J Dermatol 2019 Jan 28. Epub 2019 Jan 28.

Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14790DOI Listing
January 2019
1 Read

Atrophic palmar papules in lupus erythematosus: are inverse Gottron papules specific for dermatomyositis?

Rheumatology (Oxford) 2019 Feb;58(2):370

Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key247DOI Listing
February 2019
1 Read

Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.

Rheumatology (Oxford) 2019 Jan 23. Epub 2019 Jan 23.

Dipartimento di Neuroscienze Riabilitazione Oftalmologia Genetica e Scienze Materno-Infantili, Università degli Studi di Genova, Genoa, Italy.

Objective: To develop a composite DAS for JDM and provide preliminary evidence of its validity.

Methods: The Juvenile DermatoMyositis Activity Index (JDMAI) is composed of four items: physician's global assessment of overall disease activity; parent's/child's global assessment of child's wellbeing; measurement of muscle strength; and assessment of skin disease activity. The score of the JDMAI is the arithmetic sum of the scores of each individual component. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/rheumatology/advance-article/doi/10
Publisher Site
http://dx.doi.org/10.1093/rheumatology/key421DOI Listing
January 2019
2 Reads

Severe Thrombocytopenia in Patient with Dermatomyositis.

Curr Health Sci J 2018 Apr-Jun;44(2):192-196. Epub 2018 Mar 27.

Department of Rheumatology, University of Medicine and Pharmacy of Craiova, Romania.

Dermatomyositis (DM) is part of a heterogeneous group of systemic diseases called idiopathic inflammatory myopathies. As in other autoimmune connective tissue diseases (CTD), abnormalities of hematopoietic tissue and/or peripheral blood cells may develop and represent an important prognostic factor. Most common CTD associated with thrombocytopenia (TP) are systemic lupus erythematosus and antiphospholipid syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12865/CHSJ.44.02.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320470PMC
March 2018
1 Read

Examining Cutaneous Disease Activity As An Outcome Measure For Clinical Trials In Dermatomyositis.

J Am Acad Dermatol 2019 Jan 24. Epub 2019 Jan 24.

Corporal Michael J. Crescenz VAMC, Philadelphia, PA; Dept of Dermatology, UPenn, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.028DOI Listing
January 2019
1 Read

Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis.

Cytokine 2019 Apr 23;116:13-20. Epub 2019 Jan 23.

Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address:

Background: S100A11 (calgizzarin), a member of the S100 family, is associated with oncogenesis, inflammation and myocardial damage. Our aim was to analyse S100A11 in idiopathic inflammatory myopathies (IIMs) and its association with disease activity features and cancer development.

Methods: S100A11 in muscle was determined by immunohistochemistry in polymyositis (PM), dermatomyositis (DM), myasthenia gravis (MG) and in subjects without autoimmune inflammatory disease (HC). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10434666193001
Publisher Site
http://dx.doi.org/10.1016/j.cyto.2018.12.023DOI Listing
April 2019
2 Reads

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report.

Allergy Asthma Clin Immunol 2019 17;15. Epub 2019 Jan 17.

3Department of Medicine, Western University, London, ON Canada.

Background: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-019-0319-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756PMC
January 2019
1 Read

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.

JAMA Dermatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.5215DOI Listing
January 2019
1 Read

Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies.

Adv Rheumatol 2019 Jan 22;59(1). Epub 2019 Jan 22.

Disciplina de Reumatologia, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3° andar, sala 3150 - Cerqueira César, Sao Paulo, CEP: 01246-903, Brazil.

Background: Recommendations of the Myopathy Committee of the Brazilian Society of Rheumatology for the management and therapy of systemic autoimmune myopathies (SAM).

Main Body: The review of the literature was done in the search for the Medline (PubMed), Embase and Cochrane databases including studies published until June 2018. The Prisma was used for the systematic review and the articles were evaluated according to the levels of Oxford evidence. Read More

View Article

Download full-text PDF

Source
https://advancesinrheumatology.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s42358-019-0048-xDOI Listing
January 2019
6 Reads

18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.

Nucl Med Commun 2019 Jan 18. Epub 2019 Jan 18.

Nuclear Medicine Department, Lady Davis Institute, Jewish General Hospital.

Background: To compare the performance of fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) and conventional tests for cancer screening in autoimmune inflammatory myopathy (AIM) patients.

Patients And Methods: We carried out a retrospective cohort study of AIM patients from one academic center in Montreal, Canada, classified using myositis-specific antibodies, who underwent F-FDG PET/CT between April 2005 and February 2018 and were followed up on average 3.5±2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000981DOI Listing
January 2019
5 Reads

Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication.

J Clin Rheumatol 2019 Jan 18. Epub 2019 Jan 18.

Department of Pediatric MedicineIPGMER & SSKM HospitalKolkata, India

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000991DOI Listing
January 2019
2 Reads

Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?

Adv Rheumatol 2018 Sep 5;58(1):28. Epub 2018 Sep 5.

Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Rua Joel Jorge de Melo, 600 apto 121, Vila Mariana, São Paulo, SP, 04128-081, Brazil.

Background: Association between periodontal disease and dyslipidemia was recently reported in healthy adults. However, a systematic evaluation of concomitant periodontal diseases and lipid profile was not carried out in juvenile dermatomyositis (JDM). A cross-section study was performed in 25 JDM patients and 25 healthy controls, assessing demographic data, periodontal evaluation, fasting lipoproteins and anti-lipoprotein lipase antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-018-0024-xDOI Listing
September 2018
1 Read

Comparison between treatment naive juvenile and adult dermatomyositis muscle biopsies: difference of inflammatory cells phenotyping.

Adv Rheumatol 2018 Oct 26;58(1):37. Epub 2018 Oct 26.

Laboratório de Biologia Molecular e Celular, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

Background: Different inflammatory cells (i.e., CD4, CD8, CD20 and CD68) are involved in pathogenesis of DM muscle. Read More

View Article

Download full-text PDF

Source
https://advancesinrheumatology.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s42358-018-0037-5DOI Listing
October 2018
3 Reads

Relevance of serum angiogenic cytokines in adult patients with dermatomyositis.

Adv Rheumatol 2018 Jul 31;58(1):17. Epub 2018 Jul 31.

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3° andar, sala 3150 - Cerqueira César, Sao Paulo, CEP: 01246-903, Brazil.

Background: Until now, there are few studies evaluating serum levels of angiogenic cytokines in dermatomyositis (DM). Therefore, the aims of the present study were: (a) to analyze systematically and simultaneously serum levels of angiogenin (ANG), angiopoietin (ANGPT)-1, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)-1 and - 2, platelet derived growth factor (PDGF)-AA and -BB in DM; (b) to correlate the serum level of these cytokines with the DM clinical and laboratory features.

Methods: This is a cross sectional study, in which 48 patients with DM aged 18 to 45 years were gender-, age- and ethnicity-matched with 48 healthy individuals (control group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-018-0018-8DOI Listing
July 2018
1 Read

Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series.

Adv Rheumatol 2018 Oct 22;58(1):34. Epub 2018 Oct 22.

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3 andar, sala 3150 - Cerqueira César, CEP 01246-903, Sao Paulo, Brazil.

Background: Currently, there are only few studies (mostly case reports or case series) on mycophenolate mofetil (MMF) in patients with systemic autoimmune myopathies (SAM). Therefore, the goal of the present study was to evaluate the safety and efficacy of MMF (monotherapy or coadjuvant drug) in a specific sample of patients with refractory SAM: dermatomyositis, polymyositis, anti-synthetase syndrome or clinically amyopathic dermatomyositis.

Methods: A case series including 20 consecutive adult patients with refractory SAM from 2010 to 2016 was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-018-0035-7DOI Listing
October 2018
1 Read

Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.

Adv Rheumatol 2018 Sep 18;58(1):31. Epub 2018 Sep 18.

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

Background: Interpretation of rituximab efficacy for refractory idiopathic inflammatory myopathies (IIM) is hampered by the absence of a uniform definition of refractory myositis and clinical response. Therefore, rigorous criteria of refractoriness, together with a homogenous definition of clinical improvement, were used to evaluate rituximab one-year response.

Methods: A retrospective cohort study including 43 IIM (15 antisynthetase syndrome, 16 dermatomyositis, 12 polymyositis) was conducted. Read More

View Article

Download full-text PDF

Source
https://advancesinrheumatology.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s42358-018-0030-zDOI Listing
September 2018
9 Reads

Physical exercise among patients with systemic autoimmune myopathies.

Adv Rheumatol 2018 May 24;58(1). Epub 2018 May 24.

Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3° andar, sala 3150 - Cerqueira César, Sao Paulo, 01246-903, Brazil.

Systemic autoimmune myopathies (SAMs) are a heterogeneous group of rare systemic autoimmune diseases that primarily affect skeletal muscles. Patients with SAMs show progressive skeletal muscle weakness and consequent functional disabilities, low health quality, and sedentary lifestyles. In this context, exercise training emerges as a non-pharmacological therapy to improve muscle strength and function as well as the clinical aspects of these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-018-0004-1DOI Listing
May 2018
1 Read